Özet:

INTRODUCTION: To investigate the visual acuity, intraocular pressure and central macular thickness response after intravitreal triamcinolone acetonide injection (IVTA 0.1 ml/4 mg) for treating diabetic macular edema (DME). METHODS: Fifty eyes of 50 patients with DME were included in the study. Triamcinolone acetonide (TA) 0.1 ml/4mg was injected intravitreally under topical anesthesia. The best corrected visual acuity (BCVA), intraocular pressure (IOP) and central macular thickness (CMT) with optic cohorence tomography (OCT) values before and 1 week, 1 month, 3 months and 6 months after IVTA injection were noted. RESULTS: The mean age of patients were 59.60±11.62 (35-80 year), the mean follow-up period was 7.36±4.51 months (6-24 months). The visual acuity of the patients were 0.19±0.16 before injection and after injection 1. week 0.20±0.16, 1. month 0.26±0.20, 3. months 0.28±0.20 and 6. months 0.23±0.21. The visual acuity improved significiantly from baseline at the first week, first months, 3. months and 6. months (p<0.05). The mean IOP before injection was 15,64±2,71 mmHg, at 1. week, 1. month, 3. months and 6. months after the injection were respectively 17,68±2,38 mmHg, 20,82±3,14 mmHg, 18,57±1,99 mmHg, 16,50±2,17 mmHg. The mean CMT at baseline, 1. month, 3. months and 6. months were respectively 501,39±154,50 μm, 304,86±145,40 μm, 252,50±156,26 μm, 362,56±163,44 μm. DISCUSSION AND CONCLUSION: In diabetic macular edema, intravitreal triamcinolone injection cause significiant anatomical improvement demonstrated by OCT, and functional improvement in short-term. The most common complications are intraocular pressure elevation and cataract development in the long-term.

Anahtar Kelimeler: